Efficacy of bioreactor-activated bone substitute with bone marrow nuclear cells on fusion rate and fusion mass microarchitecture in sheep.
bone graft substitute
bone marrow nuclear cells
bone microarchitecture
flow perfusion bioreactor
immunohistochemistry
spinal fusion
Journal
Journal of biomedical materials research. Part B, Applied biomaterials
ISSN: 1552-4981
Titre abrégé: J Biomed Mater Res B Appl Biomater
Pays: United States
ID NLM: 101234238
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
02
04
2021
received:
09
04
2020
accepted:
22
02
2022
pubmed:
3
3
2022
medline:
14
6
2022
entrez:
2
3
2022
Statut:
ppublish
Résumé
Bioreactors have been used for bone graft engineering in pre-clinical investigations over the past 15 years. The ability of bioreactor-incubated bone marrow nuclear cells (BMNCs) to enhance bone-forming potential varies significantly, and the three-dimensional (3D) distribution of BMNCs within the scaffold is largely unknown. The aims of this study were (1) to investigate the efficacy of a carbonated hydroxyapatite (CHA) with/without BMNCs on spine fusion rate and fusion mass microarchitecture using a highly challenging two-level posterolateral spine fusion without instrumentation; and (2) to evaluate 3D distribution of BMNCs within scaffolds characterized by immunohistochemistry. Fusion rate and fusion mass were quantified by micro-CT, microarchitectural analysis, and histology. While the homogenous 3D distribution of BMNCs was not observed, BMNCs were found to migrate towards a substitute core. In the autograft group, the healing rate was 83.3%, irrespective of the presence of BMNCs. In the CHA group, also 83.3% was fused in the presence of BMNCs, and 66.7% fused without BMNCs. A significant decrease in the fusion mass porosity (p = .001) of the CHA group suggested the deposition of mineralized bone. The autograft group revealed more bone, thicker trabeculae, and better trabecular orientation but less connection compared to the CHA group. Immunohistochemistry confirmed the ability of bioreactors to incubate a large-sized substitute coated with viable BMNCs with the potential for proliferation and differentiation. These findings suggested that a bioreactor-activated substitute is comparable to autograft on spine fusion and that new functional bone regeneration could be achieved by a combination of BMNCs, biomaterials, and bioreactors.
Substances chimiques
Bone Substitutes
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1862-1875Subventions
Organisme : European Commission 6th framework program
ID : NMP3-CT-2003-505711
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Campana V, Milano G, Pagano E, et al. Bone substitutes in orthopaedic surgery: from basic science to clinical practice. J Mater Sci Mater Med. 2014;25(10):2445-2461. doi:10.1007/s10856-014-5240-2
Marcacci M, Kon E, Moukhachev V, et al. Stem cells associated with macroporous bioceramics for long bone repair: 6- to 7-year outcome of a pilot clinical study. Tissue Eng. 2007;13(5):947-955. doi:10.1089/ten.2006.0271
Cancedda R, Giannoni P, Mastrogiacomo M. A tissue engineering approach to bone repair in large animal models and in clinical practice. Biomaterials. 2007;28(29):4240-4250. doi:10.1016/j.biomaterials.2007.06.023
Evans NR, Davies EM, Dare CJ, Oreffo RO. Tissue engineering strategies in spinal arthrodesis: the clinical imperative and challenges to clinical translation. Regen Med. 2013;8(1):49-64. doi:10.2217/rme.12.106
Mageed AS, Pietryga DW, DeHeer DH, West RA. Isolation of large numbers of mesenchymal stem cells from the washings of bone marrow collection bags: characterization of fresh mesenchymal stem cells. Transplantation. 2007;83(8):1019-1026. doi:10.1097/01.tp.0000259752.13304.0b
Banfi A, Bianchi G, Notaro R, Luzzatto L, Cancedda R, Quarto R. Replicative aging and gene expression in long-term cultures of human bone marrow stromal cells. Tissue Eng. 2002;8(6):901-910. doi:10.1089/107632702320934001
Bruder SP, Jaiswal N, Haynesworth SE. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem. 1997;64(2):278-294. http://www.ncbi.nlm.nih.gov/pubmed/9027588
Izadpanah R, Kaushal D, Kriedt C, et al. Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res. 2008;68(11):4229-4238. doi:10.1158/0008-5472.CAN-07-5272
Peroglio M, Gaspar D, Zeugolis DI, Alini M. Relevance of bioreactors and whole tissue cultures for the translation of new therapies to humans. J Orthop Res. 2018;36(1):10-21. doi:10.1002/jor.23655
Braccini A, Wendt D, Jaquiery C, et al. Three-dimensional perfusion culture of human bone marrow cells and generation of osteoinductive grafts. Stem Cells. 2005;23(8):1066-1072. doi:10.1634/stemcells.2005-0002
Ding M, Koroma KE, Sorensen JR, et al. Collagen-hydroxyapatite composite substitute and bone marrow nuclear cells on posterolateral spine fusion in sheep. J Biomater Appl. 2019;34(3):365-374. doi:10.1177/0885328219851315
Sorensen JR, Koroma KE, Ding M, et al. Effects of a perfusion bioreactor activated novel bone substitute in spine fusion in sheep. Eur Spine J. 2012;21(9):1740-1747. doi:10.1007/s00586-012-2421-x
Braccini A, Wendt D, Farhadi J, Schaeren S, Heberer M, Martin I. The osteogenicity of implanted engineered bone constructs is related to the density of clonogenic bone marrow stromal cells. J Tissue Eng Regen Med. 2007;1(1):60-65. doi:10.1002/term.11
Ding M, Henriksen SS, Wendt D, Overgaard S. An automated perfusion bioreactor for the streamlined production of engineered osteogenic grafts. J Biomed Mater Res B Appl Biomater. 2016;104(3):532-537. doi:10.1002/jbm.b.33407
Ding M, Odgaard A, Hvid I. Accuracy of cancellous bone volume fraction measured by micro-CT scanning. J Biomech. 1999;32:323-326.
Ding M. Microarchitectural adaptations in aging and osteoarthrotic subchondral bone issues. Acta Orthop Suppl. 2010;81(340):1-53. doi:10.3109/17453671003619037
Odgaard A. Three-dimensional methods for quantification of cancellous bone architecture. Bone. 1997;20(4):315-328.
Ding M, Cheng L, Bollen P, Schwarz P, Overgaard S. Glucocorticoid induced osteopenia in cancellous bone of sheep: validation of large animal model for spine fusion and biomaterial research. Spine. 2010;35(4):363-370. doi:10.1097/BRS.0b013e3181b8e0ff
Rhys EJ. Bone formation biology and biochemistry. In: Coe FL, Favus MJ, eds. Disorders of Bone and Mineral Metabolism. Raven PR; 2002:241-260.
Schonk DM, Kuijpers HJ, van Drunen E, et al. Assignment of the gene(s) involved in the expression of the proliferation-related Ki-67 antigen to human chromosome 10. Hum Genet. 1989;83(3):297-299.
Eriksson JE, Dechat T, Grin B, et al. Introducing intermediate filaments: from discovery to disease. J Clin Invest. 2009;119(7):1763-1771.
Yang R, Davies CM, Archer CW, Richards RG. Immunohistochemistry of matrix markers in Technovit 9100 new-embedded undecalcified bone sections. Eur Cell Mater. 2003;6:57-71; discussion 71. http://www.ncbi.nlm.nih.gov/pubmed/14722903
Steinmann JC, Herkowitz HN. Pseudarthrosis of the spine. Clin Orthop Relat Res. 1992;284:80-90. http://www.ncbi.nlm.nih.gov/pubmed/1395317
Boatright KC, Boden SC. Biology of spine fusion. Biology and clinical applications. In: Friedlaender JRLAGE, ed. Bone Regeneration and Repair: Biology and Clinical Applications. Humana Press Inc; 2005.
Ludwig SC, Kowalski JM, Boden SD. Osteoinductive bone graft substitutes. Eur Spine J. 2000;9(Suppl 1):S119-S125. http://www.ncbi.nlm.nih.gov/pubmed/10766068
Schimandle J, Boden SD. Bone substitutes for lumbar fusion:present and future. Operative Techniquesin Orthopaedics. 1997;7(1):60-67.
Kruyt MC, Wilson CE, de Bruijn JD, et al. The effect of cell-based bone tissue engineering in a goat transverse process model. Biomaterials. 2006;29:5099-5106.
LeGeros RZ. Properties of osteoconductive biomaterials: calcium phosphates. Clin Orthop Relat Res. 2002;395:81-98. http://www.ncbi.nlm.nih.gov/pubmed/11937868
Halstenberg S, Unger RE, Kirkpatrick CJ. Differentiation of osteoblast cell lines CAL 72 and MG 63 on carbonated porous hydroxyapatite. Paper presented at the ESB 2006 - 20th European Conference on Biomaterials, Nantes, France, September 27th-October 1st, 2006.
Brydone AS, Meek D, Maclaine S. Bone grafting, orthopaedic biomaterials, and the clinical need for bone engineering. Proc Inst Mech Eng H. 2010;224(12):1329-1343. doi:10.1243/09544119JEIM770
Meinel L, Karageorgiou V, Fajardo R, et al. Bone tissue engineering using human mesenchymal stem cells: effects of scaffold material and medium flow. Ann Biomed Eng. 2004;32(1):112-122. http://www.ncbi.nlm.nih.gov/pubmed/14964727
Burdick JA, Vunjak-Novakovic G. Engineered microenvironments for controlled stem cell differentiation. Tissue Eng Part A. 2009;15(2):205-219. doi:10.1089/ten.tea.2008.0131
Janssen FW, Oostra J, Oorschot A, van Blitterswijk CA. A perfusion bioreactor system capable of producing clinically relevant volumes of tissue-engineered bone: in vivo bone formation showing proof of concept. Biomaterials. 2006;27(3):315-323. doi:10.1016/j.biomaterials.2005.07.044
Simmons AD, Williams C 3rd, Degoix A, Sikavitsas VI. Sensing metabolites for the monitoring of tissue engineered construct cellularity in perfusion bioreactors. Biosens Bioelectron. 2017;90:443-449. doi:10.1016/j.bios.2016.09.094
Hejbol EK, Sellathurai J, Nair PD, Schroder HD. Injectable scaffold materials differ in their cell instructive effects on primary human myoblasts. J Tissue Eng. 2017;8:2041731417717677. doi:10.1177/2041731417717677
Cheng G, Markenscoff P, Zygourakis K. A 3D hybrid model for tissue growth: the interplay between cell population and mass transport dynamics. Biophys J. 2009;97(2):401-414. doi:10.1016/j.bpj.2009.03.067
Zhou Y, Fan W, Prasadam I, Crawford R, Xiao Y. Implantation of osteogenic differentiated donor mesenchymal stem cells causes recruitment of host cells. J Tissue Eng Regen Med. 2015;9(2):118-126. doi:10.1002/term.1619